IP Library Granted Patent US 8,790,621
Granted Patent B2
US 8,790,621 · App. 13/640,698 · Granted Jul 29, 2014

Nanoparticles and nanoparticle compositions

Inventor: Yan Zhao (Ames, IA)
Assignee: Iowa State University Research Foundation, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,790,621
App. No.
13/640,698
Granted
Jul 29, 2014
Kind
B2
Abstract

The invention provides multivalent surface-crosslinked micelle (SCM) particles, crosslinked reverse micelle (CRM) particles, and methods of making and using them. The SCM particles can be used, for example, to inhibit a virus or bacteria from binding to a host cell. The inhibition can be used in therapy for the flu, cancer, or AIDS. The CRM particles can be used, for example, to prepare metal nanoparticles or metal alloy nanoparticles, or they can be used in catalytic reactions.

Claims (13)

1. An organic particle comprising surface crosslinked non-polymeric organic amphiphiles;

wherein polar head groups of the amphiphiles are covalently crosslinked to each other at the surface of the particle through triazole groups, and tail groups of the amphiphiles are arranged toward the interior of the particle; and the particle is water-soluble.

2. The organic particle of claim 1 wherein the tail groups of the amphiphiles arranged toward the interior of the particle are non-polar hydrocarbon or fluorocarbon tail groups, polar tail groups, or a combination thereof.

3. The organic particle of claim 2 wherein the non-polar tail groups of the amphiphiles comprise one or more (C 6 -C 22 ) alkyl groups, (C 6 -C 22 ) fluoroalkyl groups, or a combination thereof, and wherein the non-polar tail groups optionally comprise one or more of ester, imine, boronate, disulfide groups or salt bridges linking a portion of the tail to a head group of the amphiphile or another portion of the tail that is linked to the head group of the amphiphile.

4. The organic particle of claim 1 wherein the tail groups of the amphiphiles are non-polar and the particle has a hydrophobic core and a hydrophilic exterior; or the tail groups of the amphiphiles are polar and the particle has a hydrophilic core and a hydrophilic exterior.

5. The organic particle claims 1 wherein the particle is in the form of a liposome comprising a bilayer of amphiphiles, and the bilayer comprises one or more water compartments between the bilayer of amphiphiles.

6. The organic particle of claim 1 wherein the particle comprises one or more cargo molecules within the particle or at the surface of the particle.

7. The organic particle of claim 6 wherein the cargo molecules comprise one or more of a drug, an organic nanoparticle, an inorganic nanoparticle, a fluorophore, a diagnostic agent, and a catalysts.

8. The organic particle of claim 1 wherein the surface of the particle comprises one or more surface groups comprising water-soluble polymers, fluorophores, biological ligands, nucleic acids, nucleic acid analogues, catalysts, or a combination thereof.

9. The organic particle of claim 8 wherein the surface groups are receptors or ligands for corresponding ligands or receptors on a biological host.

10. The organic particle of claim 1 wherein the surface crosslinking can be cleaved by heat, by a change in pH, by a reducing agent, or by a combination thereof.

11. A delivery system comprising a plurality of particles of any one of claims 6 , and a pharmaceutically acceptable diluent or carrier.

12. A therapeutic method comprising administering to a patient in need therapy an effective amount of the delivery system of claim 11 , wherein the surface crosslinking of the particles encapsulate one or more drugs, the surface crosslinking of the particles is cleaved in vivo, and the drug of the particles is released into the body of the patient, thereby providing the drug to the patient.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 30, 2013
From: IOWA STATE UNIVERSITY OF SCIENCE AND TECHNOLOGY
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 030920/0003 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2012
From: ZHAO, YAN
To: IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
Reel/Frame 029582/0172 →
Continuity (2)
Provisional Application 61323072 · Apr 12, 2010
Related Publication 20130101516A1 · Apr 25, 2013